Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease

Circulation

Volumn 87, Issue 6, 1993, Pages 1781-1791

  Brown, B Greg ^a,b   Zhao, Xue Qiao ^a   Sacco, Dianne E ^a   Albers, John J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Clinical Progress Series; Coronary artery disease; Lipids

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER; COLESTIPOL; COLESTYRAMINE; COLLAGEN; ELASTIN; ENDOTHELIUM DERIVED RELAXING FACTOR; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; NITRIC OXIDE; PHOSPHOLIPID;

ARTERIOGRAPHY; ARTERY OCCLUSION; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL TONE; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DIET; DISEASE SEVERITY; EXERCISE; FIBROGENESIS; FOAM CELL; HEART INFARCTION; HISTOLOGY; HUMAN; LIFESTYLE; LIPID STORAGE; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUDDEN DEATH;

ANTILIPEMIC AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DIETARY FATS; EXERCISE; FEMALE; HUMAN; HYPERLIPIDEMIA; LIFE STYLE; LIPIDS; MALE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027322448     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.87.6.1781     Document Type: Article

References (85)

1. Demer LL, Gould KL, Goldstein RA, Kirkeeide RL, Mullani NA, Smalling RW, Nishikawa A, Merhige ME: Assessment of coronary artery disease severity by positron emission tomography: Comparison with quantitative arteriography in 193 patients. Circulation 1989;79:825-835
2. Klocke FJ: Measurements of coronary flow reserve: Defining pathophysiology versus making decisions about patient care. Circulation 1987;76:1183-1189
3. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-1051
4. Nabel EG, Selwyn AP, Ganz P: Large coronary arteries in humans are responsive to changing blood flow: An endothelium-dependent mechanism that fails in patients with atherosclerosis. J Am Coll Cardiol 1990;16:349-356
5. Kaski JC, Crea F, Meran DO, Rodriguez LG, Aranjo L, Chierchia S, Davies G, Maseri A: Local coronary supersensitivity to diverse vasoconstrictive stimuli in patients with variant angina. Circulation 1986;74:1255-1265
6. Cannon RO, Camici PG, Epstein SE: Pathophysiological dilemma of syndrome X. Circulation 1992;85:883-892
7. Loscalzo J, Dzau VJ: Flow activates an endothelium potassium channel to release an endogenous nitrovasodilator. J Clin Invest 1991;88:1663-1671
8. Brown BG, Gallery CA, Badger RS, Kennedy JW, Mathey D, Bolson EL, Dodge HT: Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: Quantitative angiographic observations. Circulation 1986;73:653-661
9. TIMI IIIA Investigators: Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest: Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation 1993;87:38-52
10. Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-250, 310-318
11. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ: Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-1375
12. Langille BL, O'Donnell F: Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science 1986;231:405-407
13. Jaffe RB, Glancy DC, Epstein SE, Brown BG, Morrow AG: Coronary arterial-right heart fistulae: Long-term observations in seven patients. Circulation 1973;47:133-143
14. McLenachan JM, Williams JK, Fish RD, Ganz P, Selwyn AP: Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. Circulation 1991;84:1273-1278
15. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;299:373-376
16. Furchgott RF, Vanhoutte PM: Endothelium-derived relaxing and contracting factors. FASEB J 1989;3:2007-2018
17. Selke FW, Armstrong ML, Harrison DG: Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation 1990;81:1568-1593
18. Wissler RW, Vesselinovitch D: Can atherosclerotic plaques regress? Anatomic and biochemical evidence from nonhuman animal models. Am J Cardiol 1990;65:33-40
19. Armstrong ML, Megan MB: Lipid depletion in atheromatous coronary arteries in rhesus monkeys after regression diets. Circ Res 1972;30:675-680
20. Armstrong MC, Megan MB: Arterial fibrous protein in cynomolgous monkeys after atherogenic and regression diets. Circ Res 1975;36:256-261
21. Clarkson TB, Bond MG, Bullock BC, Marzetta CA: A study of atherosclerosis regression in Macaca mulatta: IV. Changes in coronary arteries from animals with atherosclerosis induced for 19 months and then regressed for 24 or 48 months at plasma cholesterol concentrations of 300 or 200 mg/dl. Exp Mol Pathol 1981;34: 345-368
22. Small DM, Bond MG, Waugh D, Prack M, Sawyer JK: Physiochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest 1984;73:1590-1605
23. Brown BG, Fry DL: The fate and fibrogenic potential of subintimal implants of crystalline lipid in the canine aorta: Quantitative histological and autoradiographic studies. Circ Res 1978;43:261-273
24. Carew TE, Schwenke DC, Steinberg D: An antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich streaks slowing the progression of atherosclerosis in the WHHL rabbit. Proc Natl Acad Sci U S A 1987;84:7725-7729
25. Kuo PT, Hayase K, Kostic JB, Moreyra AE: Use of combined diet and colestipol in long-term (7-7.5 years) treatment of patients with type II hyperlipoproteinemia. Circulation 1979;59:199-214
26. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, Friedewald W, Detre KM, Epstein SE: Effects of therapy with cholestyramine on progression of coronary atherosclerosis: Results of the NHLBI Type II coronary intervention study. Circulation 1984;69:313-324
27. Duffield RGM, Lewis B, Miller NE, Jamieson CW, Brunt JNH, Colchester ACF: Treatment of hyperlipidemia retards progression of symptomatic femoral atherosclerosis. Lancet 1983;ii:639-642
28. Nash DT, Gensini G, Esente P: Effect of lipid lowering therapy on the progression of coronary atherosclerosis assessed by scheduled repetitive coronary arteriography. Int J Cardiol 1982;2:43-55
29. Nikkila EA, Viikinkoski P, Valle M, Frick MH: Prevention of progression of coronary atherosclerosis by treatment of hyperlipidemia: A seven-year prospective angiographic study. Br Med J 1984;289:220-223
30. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cachin-Hamphill L: Beneficial effects of colestipol niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-3240
31. Buchwald H, Varco RL, Matts JP, Long JM, Fitch LL, Campbell GS: Effect of partial ileal bypass on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: Report of the Program on Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990;323:946-955
32. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Bould KL: Can lifestyle changes reverse coronary heart disease? Lancet 1990; 336:129-133
33. Brown BG, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan CK, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298
34. Cashin-Hemphill L, Mack WJ, Pogoda MJ, Sanmarco ME, Azen SP, Blankenhorn DH: Beneficial effects of colestipol-niacin on coronary atherosclerosis. JAMA 1990;264:3013-3017
35. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-3012
36. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, Mann JI, Swan AV: Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339: 563-569
37. Alderman E, Haskell WL, Fain JM, Superko HR, Maron DJ, Champagne MA, Mackey SF, Williams PT, Krauss RM, Farquhar JW: Beneficial angiographic and clinical response to multifactor modification in the Stanford Coronary Risk Intervention Project (SCRIP). (abstract) Circulation 1991;84(suppl II):II-140
38. Schuler G, Hambrecht R, Schlierf G, Niebauer J, Hauer K, Neumann J, Hoberg E, Drinkmann A, Bacher F, Grunze M, Kubler W: Regular physical exercise and low-fat diet: Effects on progression of coronary artery disease. Circulation 1992;86:1-11
39. Brown BG, Bolson EL, Dodge HT: Quantitative computer techniques for analyzing coronary arteriograms. Prog Cardiovasc Dis 1986;28:403-418
40. Smith EB: The relationship between plasma and tissue lipids in human atherosclerosis. Adv Lipid Res 1974;12:1-49
41. Walton KW, Williamson N: Histological and immunofluorescent studies on the evolution of the human atheromatous plaque. J Atheroscler Res 1968;8:599-624
42. Rath M, Niendorf A, Reblin T, Dietel M, Krebber H-J, Beisiegel U: Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9: 579-592
43. Cushing GL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TMA, Guyton JR, Weilbaecher D, DeBakey ME, Lawrie GM, Morrisett JD: Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at reoperation. Arteriosclerosis 1989;9:593-603
44. Gerrity RG: The role of monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 1981;103:181-190
45. Ross R: The pathogenesis of atherosclerosis: An update. N Engl J Med 1986;314:488-500
46. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-924
47. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Barnshad B, Esterson M, Fogelman AM: Minimally modified LDL stimulates monocyte endothelial interactions. J Clin Invest 1990;85:1260-1266
48. Yamaguchi J, Hoff MF: Apolipoprotein B accumulation and development of foam cell lesions in coronary arteries of hypercholesterolemic swine. Lab Invest 1984;51:325-332
49. Krempler F, Kostner GM, Roscher A, Bolzano K, Sandhofer F: The interaction of human apoB containing lipoproteins with mouse peritoneal macrophages: A comparison of Lp(a) with LDL. J Lipid Res 1984;25:283-287
50. Stary HC: Evolution and progression of atherosclerosis in the coronary arteries of children and adults, in Bates SR, Gangloff EC (eds): Atherogenesis and Aging. New York, Springer-Verlag, 1987, pp 56-63
51. Guyton JR, Klemp KF: The lipid-rich core region of human atherosclerotic fibrous plaques. Am J Pathol 1989;134:705-717
52. Fry DL: Mass transport, atherogenesis, and risk. Arteriosclerosis 1987;7:88-100
53. Guyton JR, Bocan TMA: Human aortic fibrolipid lesions: Progenitor lesions for fibrous plaques, exhibiting early formation of the cholesterol-rich core. Am J Pathol 1985;120:193-206
54. Smith EB, Evans PH, Pownham MD: Lipid in the aortic intima: The correlation of morphological and chemical characteristics. J Atheroscler Res 1967;7:171-186
55. Haust MD: The morphogenesis and fate of potential and early atherosclerotic lesions in man. Hum Pathol 1971;2:1-29
56. Guyton JR, Bocan TM, Schifani TA: Quantitative ultrastructural analysis of perifibrous lipid and its association with elastin in nonatherosclerotic human aorta. Arteriosclerosis 1985;5:644-652
57. Tracey RE, Devaney K, Kissling G: Characteristics of the plaque under a coronary thrombus. Virchows Arch Pathol Anat 1985;405: 411-427
58. Davies MJ, Krikler DM, Katz D: Atherosclerosis: Inhibition or regression as therapeutic possibilities. Br Heart J 1991;65:302-310
59. Duguid JB: Thrombosis as a factor in the pathogenesis of aortic atherosclerosis. J Pathol Bacteriol 1948;60:57-69
60. Moncada S, Palmer RM, Higgs EA: Nitric oxide physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142
61. Stamler JS, Simon DI, Osborne JA, Mullins ME, Jaraki O, Michel T, Singel DJ, Loscalzo J: S-Nitrosylation of proteins with nitric oxide-synthesis and characterization of novel biologically active compounds. Proc Natl Acad Sci U S A 1992;89:444-448
62. Chilian WM, Dellsperger KC, Layne SM, Eastham CL, Armstrong MA, Marcus ML, Heistad DD: Effects of atherosclerosis on the coronary micro-circulation. Am J Physiol 1990;258:H529-539
63. Brown BG, Lee AB, Bolson EL, Dodge HT: Reflex constriction of significant coronary stenosis as a mechanism contributing to ischemic ventricular dysfunction during isometric exercise. Circulation 1984;70:18-24
64. Hess OM, Bortone A, Eid K, Gage JE, Nonogi H, Grimm J, Krayenbuehl HP: Coronary vasomotor tone during static and dynamic exercise. Eur Heart J 1989;10(suppl F):105-110
65. Harrison DG, Armstrong ML, Freeman PC, Heistad DD: Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987;80:808-811
66. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Veksktein VI, Selwyn AP, Ganz P: Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990;81:491-497
67. Muegge A, Edwell JH, Peterson TE, Hofmeyer TG, Heistad DD, Harrison DD: Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ Res 1991;69: 1293-1300
68. The Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-364
69. Manninen V, Elo MO, Frick MH, Happa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Nikkila EA: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-651
70. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W: Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255
71. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V: Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988;12: 56-62
72. Little WC, Constantinescu M, Applegate RM, Kutcher MA, Burrows MT, Kahl FR, Santamore WP: Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988; 78:1157-1166
73. Taeymans Y, Théroux P, Lespérance J, Waters D: Quantitative angiographic morphology of the coronary artery lesions at risk of thrombotic occlusion. Circulation 1992;85:78-85
74. Brown BG, Lin J-T, Kelsey S, Passamani ER, Levy RI, Dodge HT, Detre KM: Progression of coronary atherosclerosis in patients with probable familial hypercholesterolemia: Quantitative arteriographic assessment of patients in NHLBI Type II Study. Arteriosclerosis 1989;9(suppl I):I-81-I-90
75. Webster MWI, Chesebro JH, Smith HC, Frye RL, Holmes DR, Reeder GS, Fuster V: Myocardial infarction and coronary artery occlusion: A prospective 5-year angiographic study. (abstract) J Am Coll Cardiol 1990;15(suppl A):218A
76. Constantinides P: Plaque fissures in human coronary thrombosis. J Atheroscler Res 1966;61:1-17
77. Constantinides P: Plaque hemorrhages, their genesis and their role in supraplaque thrombosis and atherogenesis, in Glagov S, Newman WP, Schaffer SA (eds): Pathobiology of the Human Atherosclerotic Plaque. New York, Springer-Verlag, 1990, pp 393-411
78. Lendon CL, Davies MJ, Born GVR, Richardson PD: Atherosclerotic plaque caps are locally weakened when macrophage density is increased. Atherosclerosis 1991;87:87-90
79. Richardson PD, Davies MJ, Born GVR: Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989;3:941-944
80. Loree HM, Kamm RD, Strongfellow RG, Lee RT: Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res 1992;71:850-858
81. Davies MJ: A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990;82(suppl II):II-38-II-46
82. Hessler JR, Morel DW, Lewis LJ, Chisolm GM: Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis 1983; 3:215-222
83. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD: Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990;344: 160-162
84. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086-1095
85. Haberland M, Fong D, Cheng L: Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 1988;24:215-218